Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

作者：Rowe Christopher C^*; Ellis Kathryn A; Rimajova Miroslava; Bourgeat Pierrick; Pike Kerryn E; Jones Gareth; Fripp Jurgen; Tochon Danguy Henri; Morandeau Laurence; O'Keefe Graeme; Price Roger; Raniga Parnesh; Robins Peter; Acosta Oscar; Lenzo Nat; Szoeke Cassandra; Salvado Olivier; Head Richard; Martins Ralph; Masters Colin L; Ames David; Villemagne Victor L

来源：Neurobiology of Aging, 2010, 31(8): 1275-1283.

DOI：10.1016/j.neurobiolaging.2010.04.007

• Alzheimer's disease
• Mild cognitive impairment
• Amyloid imaging
• Positron emission tomography
• Magnetic resonance imaging

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, a participant of the worldwide Alzheimer's Disease Neuroimaning Initiative (ADNI), performed (11)C-Pittsburgh Compound B (Pi B) scans in 177 healthy controls (HC), 57 mild cognitive impairment (MCI) subjects, and 53 mild Alzheimer's disease (AD) patients. High PiB binding was present in 33% of HC (49% in ApoE-epsilon 4 carriers vs 21% in noncarriers) and increased with age, most strongly in epsilon 4 carriers. 18% of HC aged 60-69 had high PiB binding rising to 65% in those over 80 years. Subjective memory complaint was only associated with elevated PiB binding in epsilon 4 carriers. There was no correlation with cognition in HC or MCI. PiB binding in AD was unrelated to age, hippocampal volume or memory. Beta-amyloid (A beta) deposition seems almost inevitable with advanced age, amyloid burden is similar at all ages in AD, and secondary factors or downstream events appear to play a more direct role than total beta amyloid burden in hippocampal atrophy and cognitive decline.

• 出版日期2010-8
• 单位CSIRO